NTHI is trading 5.1% down at $4.63 as a potential $75 million share issuance weighs on the stock, offsetting positive regulatory news from the Middle East.
- The company received a second IND approval in the UAE for NEO100, expanding its CNS cancer program and clinical footprint.
- A prospectus supplement outlines up to $75 million in potential share issuance through April 2026, creating a financing overhang that is pressuring the share price.
- The downward move comes despite what the company characterizes as strong clinical and regulatory momentum for its oncology pipeline.